List of Excipients in Branded Drug SUDAFED 12 HOUR

Generic Drugs Containing SUDAFED 12 HOUR

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	pseudoephedrine hydrochloride	50090-3287	CARNAUBA WAX
A-S Medication Solutions	pseudoephedrine hydrochloride	50090-3287	CELLULOSE, MICROCRYSTALLINE
A-S Medication Solutions	pseudoephedrine hydrochloride	50090-3287	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
A-S Medication Solutions	pseudoephedrine hydrochloride	50090-3287	HYPROMELLOSE
A-S Medication Solutions	pseudoephedrine hydrochloride	50090-3287	MAGNESIUM STEARATE
A-S Medication Solutions	pseudoephedrine hydrochloride	50090-3287	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in SUDAFED 12 HOUR?

# Of NDCs	Excipient
2	CARNAUBA WAX
2	CELLULOSE, MICROCRYSTALLINE
2	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
2	HYPROMELLOSE
2	MAGNESIUM STEARATE
2	POLYETHYLENE GLYCOL

SUDAFED 12 HOUR Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 9, 2026

SUDAFED 12 HOUR is an extended-release oral tablet containing 120 mg pseudoephedrine hydrochloride. Its commercial position depends primarily on brand recognition, retail distribution, compliant extended-release performance, and federal sales controls rather than on active patent exclusivity. The main excipient opportunity is to reproduce or improve the 12-hour release profile while reducing manufacturing cost, tablet size, variability, and abuse or diversion risk.

The product uses a conventional hydrophilic matrix approach. Public labeling identifies excipients including hypromellose, microcrystalline cellulose, povidone, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. The formulation is suitable for generic development, private-label products, contract manufacturing, and differentiated extended-release decongestant products.

What is SUDAFED 12 HOUR and how does its formulation work?

SUDAFED 12 HOUR contains pseudoephedrine hydrochloride as the active pharmaceutical ingredient. The labeled adult dose is one 120 mg extended-release tablet every 12 hours, with a maximum of two tablets in 24 hours for adults and children 12 years and older.[1]

Attribute	SUDAFED 12 HOUR
Active ingredient	Pseudoephedrine hydrochloride
Strength	120 mg per extended-release tablet
Dosage form	Oral extended-release tablet
Labeled duration	12 hours
Therapeutic category	Nasal decongestant
Regulatory route	OTC drug product under FDA monograph conditions
Primary release technology	Extended-release tablet matrix
Brand owner	Kenvue consumer-health portfolio
Primary commercial constraint	Federal retail-control requirements for pseudoephedrine

Pseudoephedrine is a sympathomimetic nasal decongestant. The extended-release dosage form reduces dosing frequency compared with immediate-release pseudoephedrine products.

A hydrophilic matrix tablet typically relies on hypromellose to hydrate after ingestion. The polymer forms a gel layer that limits water penetration and controls diffusion and erosion. The release rate is affected by polymer viscosity, particle size, concentration, tablet hardness, compression force, lubricant level, and dissolution conditions.

What excipients are used in SUDAFED 12 HOUR?

Public product labeling identifies the following inactive ingredients for the extended-release tablet: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.[1]

Excipient	Likely formulation function	Commercial relevance
Hypromellose	Hydrophilic release-controlling matrix and binder	Principal tool for achieving 12-hour release
Microcrystalline cellulose	Diluent, dry binder, and compressibility aid	Supports tablet strength and manufacturability
Povidone	Binder and granulation aid	Improves granule cohesion and content uniformity
Sodium starch glycolate	Superdisintegrant	Promotes tablet breakup and controls early hydration behavior
Colloidal silicon dioxide	Glidant and flow aid	Improves powder flow and reduces manufacturing variability
Magnesium stearate	Lubricant	Reduces ejection force and tooling adhesion

The combination is technically significant because extended-release tablets require a balance between matrix integrity and drug availability. Excessive disintegration can cause premature release. Excessive matrix strength can produce incomplete release or delayed onset.

How does hypromellose control pseudoephedrine release?

Hypromellose is likely the central release-controlling excipient. Upon contact with gastrointestinal fluid, it hydrates and forms a viscous gel barrier. Pseudoephedrine diffuses through the gel while the outer matrix gradually erodes.

Generic developers can adjust:

• Hypromellose substitution type and viscosity grade.
• Polymer concentration.
• Polymer particle size.
• Tablet porosity and compression force.
• Use of soluble fillers such as lactose or mannitol.
• Use of insoluble fillers such as microcrystalline cellulose.
• Lubricant concentration and mixing time.
• Tablet coating and moisture protection.

A lower-viscosity polymer may improve early release but increase the risk of rapid drug liberation. A higher-viscosity polymer may extend release but create a slower onset or incomplete dissolution. The target is a dissolution profile that matches the reference product across multiple pH conditions and agitation speeds.

Why is sodium starch glycolate included in an extended-release tablet?

Sodium starch glycolate is generally associated with rapid tablet disintegration. In a matrix system, its concentration and distribution must be controlled. It can improve tablet breakup after the release-controlling matrix has hydrated, but excessive levels may accelerate erosion and undermine the 12-hour profile.

This creates a formulation-development opportunity. Developers may test alternative superdisintegrants, lower concentrations, or direct-compression grades to improve reproducibility while preserving release performance.

What patent protection covers SUDAFED 12 HOUR?

SUDAFED 12 HOUR is not dependent on a current composition-of-matter patent for pseudoephedrine. Pseudoephedrine hydrochloride is an established active ingredient, and FDA regulation of oral nasal decongestants is governed primarily by the OTC monograph framework in 21 C.F.R. Part 341.[2]

Protection category	Relevance to SUDAFED 12 HOUR
Active-ingredient patent	No meaningful current exclusivity for pseudoephedrine hydrochloride
Core therapeutic use	Long-established use; generally not a current barrier
Extended-release formulation	Legacy formulation patents may exist, but they do not create active-ingredient exclusivity
OTC monograph compliance	Critical regulatory requirement
Brand trademark	Important commercial protection
Packaging and trade dress	Can support differentiation and shelf recognition
Manufacturing know-how	May protect process performance without blocking a compliant competitor

A definitive freedom-to-operate conclusion requires a current claim-level search covering U.S. patents, continuations, terminal disclaimers, reissues, and litigation records. The commercial conclusion is clearer: the main barrier to a compliant generic or private-label product is product development and regulatory execution, not a blocking pseudoephedrine patent.

When does SUDAFED 12 HOUR lose exclusivity?

SUDAFED 12 HOUR has no conventional small-molecule exclusivity period comparable to a newly approved prescription drug. Its commercial exclusivity is based on brand equity, retail placement, packaging, advertising, and distribution.

A competing manufacturer can pursue an OTC extended-release pseudoephedrine product if it satisfies the applicable monograph and labeling requirements. The competitor does not need to wait for expiration of a branded data-exclusivity period in the manner required for many prescription products.

The brand can still maintain a premium through:

• Consumer familiarity with the SUDAFED name.
• Pharmacy and retailer distribution.
• Recognition of the 12-hour dosing format.
• Established packaging and dosage instructions.
• Combination-product merchandising.
• Consumer trust in a national brand.

What is the FDA regulatory status of SUDAFED 12 HOUR?

Pseudoephedrine oral nasal decongestant products are regulated under the FDA OTC monograph system. The relevant monograph permits specified active ingredients, strengths, dosage forms, labeling, and directions for use.[2]

The main regulatory requirements include:

1. Use of an eligible active ingredient and strength.
2. Conformance with required labeling.
3. Appropriate warnings and directions.
4. Demonstration that the extended-release product performs consistently.
5. Compliance with current good manufacturing practice.
6. Compliance with federal requirements for pseudoephedrine sales and recordkeeping.

The FDA’s final administrative order framework for OTC monograph drugs has replaced the older monograph rulemaking process for many products, but the applicable conditions for oral nasal decongestants remain central to product development.[3]

How do federal pseudoephedrine controls affect commercial opportunities?

The Combat Methamphetamine Epidemic Act restricts retail access to pseudoephedrine products. Federal rules impose daily and monthly purchase limits, identification requirements, sales records, and controlled-access retail procedures.[4]

These restrictions influence product economics in several ways:

• Retailers may limit shelf exposure.
• Inventory management becomes more important.
• Pharmacy-counter or controlled-area placement reduces impulse purchases.
• E-commerce fulfillment requires compliance systems.
• Packaging must discourage unauthorized access.
• Retailers may favor suppliers with strong transaction and compliance infrastructure.

The product is commercially attractive where consumers value 12-hour dosing, but the category has lower frictionless availability than ordinary cough and cold products.

What excipient strategies can improve SUDAFED 12 HOUR competitors?

Lower-cost hydrophilic matrix formulation

The most direct strategy is a conventional hypromellose matrix using widely available excipients. This approach minimizes technical and regulatory risk. Developers can optimize polymer grade, filler ratio, compression force, and lubricant level to reproduce the reference dissolution profile.

The opportunity is strongest for:

• Store-brand products.
• Regional pharmacy chains.
• Contract-manufactured OTC portfolios.
• Export products where pseudoephedrine remains permitted.
• Combination products using the same tablet platform.

Direct compression

Direct compression can reduce processing steps and eliminate wet-granulation equipment. Microcrystalline cellulose, colloidal silicon dioxide, and a controlled-grade hypromellose can support this approach.

Risks include poor content uniformity, inadequate tablet hardness, segregation, and sensitivity to lubricant mixing. Pseudoephedrine hydrochloride has a high drug load at the labeled strength, so powder flow and compression behavior require close control.

Granulation-based manufacturing

Wet or dry granulation can improve flow, compressibility, and uniformity. It may be preferable when direct compression produces excessive tablet weight or variable dissolution.

Dry granulation can reduce water exposure and simplify scale-up. Wet granulation can improve powder handling but may alter polymer hydration and require tighter residual-moisture controls.

Smaller or easier-to-swallow tablets

A 120 mg pseudoephedrine dose already creates a substantial active load. A high-density formulation or multilayer design could reduce tablet dimensions, but changes to density and porosity can materially affect dissolution.

Commercial opportunities include:

• Smaller tablets for consumers with swallowing difficulty.
• Film-coated tablets with improved mouthfeel.
• Lower-friability tablets for high-volume retail distribution.
• Packaging optimized for controlled retail access.

Abuse-deterrence and diversion-resistant packaging

The primary diversion concern is pseudoephedrine extraction for illicit methamphetamine production. Packaging can reduce unauthorized access without changing the active formulation.

Potential approaches include:

• Unit-dose blister packaging.
• Tamper-evident cartons.
• Controlled-count pharmacy packs.
• Transaction-linked packaging.
• Retail-ready formats that limit open-shelf inventory.

A formulation marketed as abuse-deterrent would require evidence supporting the claim. Packaging controls are more practical and less legally complex than a new abuse-deterrent drug-delivery system.

What generic entry risks exist for SUDAFED 12 HOUR?

Generic entry risk is high because the active ingredient is old, the product is OTC, and the excipient platform is conventional. The principal development risks are technical and commercial.

Risk	Impact	Mitigation
Dissolution mismatch	Product failure or regulatory delay	Match release profile across pH and agitation conditions
Tablet-size burden	Lower consumer acceptance	Optimize density and compression
Polymer variability	Batch-to-batch release changes	Qualify multiple hypromellose suppliers
Retail restrictions	Reduced market access	Build pharmacy and compliance infrastructure
Brand discounting	Margin pressure	Use private-label pricing or differentiated packaging
Combination-product complexity	Additional regulatory work	Launch single-ingredient product first
Supply-chain concentration	Production interruption	Dual-source polymers and critical excipients

Because the product is sold through regulated channels, a low-cost formulation alone may not produce a strong commercial position. Retail execution and pseudoephedrine compliance are equally important.

Which companies are challenging the SUDAFED 12 HOUR market?

Competition comes from several groups:

• National branded manufacturers selling pseudoephedrine products.
• Store-brand pharmacy chains.
• Generic OTC manufacturers.
• Contract development and manufacturing organizations.
• Combination-product brands pairing pseudoephedrine with antihistamines or analgesics.
• Alternative decongestant products containing phenylephrine.

Pseudoephedrine has a pharmacologic and regulatory distinction from oral phenylephrine. The FDA proposed removing oral phenylephrine from the OTC monograph after concluding that available data did not support its effectiveness as an oral nasal decongestant at the reviewed dose.[5] That regulatory development may improve the relative positioning of pseudoephedrine products, although retail controls remain a constraint.

How does SUDAFED 12 HOUR compare with other decongestant products?

Product type	Active ingredient	Dosing profile	Retail access	Excipient opportunity
SUDAFED 12 HOUR	Pseudoephedrine HCl	Every 12 hours	Controlled sale	Hydrophilic matrix optimization
Immediate-release pseudoephedrine	Pseudoephedrine HCl	Typically more frequent	Controlled sale	Fast-disintegrating tablet
Oral phenylephrine	Phenylephrine HCl	Usually more frequent	Broad retail access historically	Regulatory repositioning risk
Nasal decongestant spray	Oxymetazoline or similar	Local administration	Broad retail access	Preservative and spray-device strategy
Antihistamine combination	Varies	Product-specific	Controlled or broad depending on ingredients	Multi-active compatibility

SUDAFED 12 HOUR has a clear convenience advantage over immediate-release pseudoephedrine. Its main disadvantage is restricted retail access and the need for reliable extended-release manufacturing.

What licensing and partnership opportunities exist?

No licensing deal is required to commercialize a compliant generic equivalent based on the public OTC framework. Commercial partnerships may still be valuable in four areas:

1. Contract manufacturing of high-volume extended-release tablets.
2. Private-label supply for pharmacy chains and mass retailers.
3. Excipient and formulation development with controlled-release technology providers.
4. Packaging and transaction-compliance systems for pseudoephedrine sales.

A brand owner could also license the Sudafed trademark, but such an arrangement would be separate from the technical right to manufacture a pseudoephedrine OTC product. The trademark, packaging, and advertising rights would require direct negotiation with the brand owner.

What patent litigation and Paragraph IV risks affect SUDAFED 12 HOUR?

Paragraph IV litigation is primarily associated with ANDA submissions for prescription drugs and certain abbreviated applications. A conventional OTC monograph product generally does not present the same Paragraph IV patent-certification pathway as a patented prescription product.

The more relevant legal risks are:

• Trademark infringement.
• Trade-dress disputes.
• False or misleading comparative advertising.
• Unauthorized use of branded packaging.
• Patent claims directed to a specific controlled-release formulation.
• Regulatory enforcement for noncompliant labeling or sales controls.

A competitor using a different matrix formulation and its own packaging would face a substantially different risk profile from a company copying the brand’s trade dress or asserting equivalence without supporting data.

What revenue exposure does SUDAFED 12 HOUR create?

Publicly available company reporting generally does not isolate revenue for a single SKU such as SUDAFED 12 HOUR. The commercial exposure is therefore assessed at the portfolio level rather than through a standalone product revenue figure.

Revenue drivers include:

• Seasonal respiratory illness demand.
• Market share of 12-hour products.
• Retail access to pseudoephedrine.
• Price premium over store-brand equivalents.
• Consumer preference for pseudoephedrine over alternative decongestants.
• Retailer inventory and transaction restrictions.

The highest-value opportunity is usually not a new excipient alone. It is a reliable, low-cost extended-release platform combined with private-label distribution and compliant pharmacy-channel execution.

Key Takeaways

• SUDAFED 12 HOUR contains 120 mg pseudoephedrine hydrochloride in an extended-release tablet.
• Hypromellose is the principal release-controlling excipient; microcrystalline cellulose, povidone, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate support manufacture and performance.
• The product has limited dependence on active patent exclusivity.
• Brand, trademark, packaging, retail placement, and pseudoephedrine transaction controls are more important than patent life.
• Generic and private-label entry risk is high because the active ingredient and formulation technology are established.
• The strongest excipient opportunity is dissolution-profile matching with lower-cost, scalable matrix-tablet manufacturing.
• Packaging and compliance infrastructure can create more commercial value than a highly novel excipient system.
• The principal regulatory pathway is OTC monograph compliance, not a conventional prescription-drug Paragraph IV strategy.
• Product differentiation can focus on tablet size, swallowability, packaging security, private-label economics, and combination-product positioning.

FAQs

Is SUDAFED 12 HOUR an extended-release formulation?

Yes. It is a 120 mg pseudoephedrine hydrochloride extended-release tablet labeled for dosing every 12 hours.[1]

Can a generic manufacturer use the same excipients as SUDAFED 12 HOUR?

Generally, yes, if the resulting product complies with applicable FDA requirements and does not infringe a valid formulation or manufacturing claim. Excipient identity alone does not establish product equivalence.

Does hypromellose create patent protection for a pseudoephedrine product?

No. Hypromellose is a widely used pharmaceutical excipient. Patent risk would depend on the specific composition, polymer grade, concentration, process, and claim scope, not merely on using hypromellose.

Is pseudoephedrine subject to special retail restrictions?

Yes. Federal law imposes purchase limits, identification requirements, transaction records, and controlled-access requirements for pseudoephedrine products.[4]

Is SUDAFED 12 HOUR protected by FDA exclusivity?

It does not have the type of new-drug exclusivity associated with a recently approved prescription product. Commercial protection is driven mainly by the Sudafed trademark, brand equity, distribution, packaging, and retail execution.

References

1. Kenvue Brands LLC. (n.d.). SUDAFED 12 HOUR nasal decongestant extended-release tablets: Drug facts. DailyMed, U.S. National Library of Medicine.

2. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. U.S. Government Publishing Office.

3. U.S. Food and Drug Administration. (2022). Over-the-counter monograph drug products: Administrative order process. FDA.

4. U.S. Drug Enforcement Administration. (2024). Pseudoephedrine and ephedrine retail sales requirements. U.S. Department of Justice.

5. U.S. Food and Drug Administration. (2023). Proposal to remove oral phenylephrine from the over-the-counter monograph. FDA.